114 related articles for article (PubMed ID: 3039014)
1. Potency stability of recombinant (Serine-17) human interferon-beta.
Geigert J; Ziegler DL; Panschar BM; Creasey AA; Vitt CR
J Interferon Res; 1987 Apr; 7(2):203-11. PubMed ID: 3039014
[TBL] [Abstract][Full Text] [Related]
2. The long-term stability of recombinant (serine-17) human interferon-beta.
Geigert J; Panschar BM; Fong S; Huston HN; Wong DE; Wong DY; Taforo C; Pemberton M
J Interferon Res; 1988 Aug; 8(4):539-47. PubMed ID: 3171246
[TBL] [Abstract][Full Text] [Related]
3. An Albumin-Free Formulation for Escherichia coli-Derived Interferon Beta-1b with Decreased Immunogenicity in Immune Tolerant Mice.
Abdolvahab MH; Fazeli A; Radmalekshahi M; Nejadnik MR; Fazeli MR; Schellekens H
J Interferon Cytokine Res; 2016 Mar; 36(3):192-203. PubMed ID: 26824268
[TBL] [Abstract][Full Text] [Related]
4. [Properties of human alpha-interferon F and hybrid interferon F/D obtained from recombinant bacteria compared to the properties of an interferon preparation from human leukocytes].
Ovchinnikov IuA; Sverdlov ED; Tsarev SA; Monastyrskaia GS; Khodkova EM
Dokl Akad Nauk SSSR; 1983; 268(4):996-1000. PubMed ID: 6187523
[No Abstract] [Full Text] [Related]
5. Comparison of an antiviral activity of recombinant consensus interferon with recombinant interferon-alpha-2b.
Koyama AH; Arakawa T; Adachi A
Microbes Infect; 1999 Nov; 1(13):1073-7. PubMed ID: 10572309
[TBL] [Abstract][Full Text] [Related]
6. Synergistic anticellular and antiviral activities of human recombinant interferon-gamma and -beta.
Gomi K; Kimura H; Okabe M; Oka T; Morimoto M
J Pharmacobiodyn; 1986 Nov; 9(11):871-8. PubMed ID: 3031263
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, antiviral activity, and conformational characterization of mouse-human alpha-interferon hybrids.
Raj NB; Israeli R; Kelley KA; Leach SJ; Minasian E; Sikaris K; Parry DA; Pitha PM
J Biol Chem; 1988 Jun; 263(18):8943-52. PubMed ID: 2837469
[TBL] [Abstract][Full Text] [Related]
8. A recombinant human interferon-alpha B/D hybrid with a broad host-range.
Horisberger MA; de Staritzky K
J Gen Virol; 1987 Mar; 68 ( Pt 3)():945-8. PubMed ID: 3029315
[TBL] [Abstract][Full Text] [Related]
9. Serum protein masking of the thermal sensitivity of the antiviral activity of purified human beta interferon: implications for clinical studies.
Cook AW; Nidzgorski F; Came P; Mann G; Carter WA; Roane PR
J Biol Response Mod; 1986 Dec; 5(6):499-503. PubMed ID: 3025378
[TBL] [Abstract][Full Text] [Related]
10. Comparative effects of interferon-consensus 1, interferon-alpha 2a, and interferon-beta 1b on HLA expression and lymphoproliferation: a preclinical model for treatment of multiple sclerosis.
Dhib-Jalbut S; Jiang H; Xia Q; Blatt L; Johnson KP; Hilt D
J Interferon Cytokine Res; 1996 Mar; 16(3):195-200. PubMed ID: 8697141
[TBL] [Abstract][Full Text] [Related]
11. Effect of recombinant interferon-beta ser on primary human tumor colony-forming units.
Von Hoff DD; Huong AM
J Interferon Res; 1988 Dec; 8(6):813-20. PubMed ID: 3230332
[TBL] [Abstract][Full Text] [Related]
12. Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta).
Runkel L; Meier W; Pepinsky RB; Karpusas M; Whitty A; Kimball K; Brickelmaier M; Muldowney C; Jones W; Goelz SE
Pharm Res; 1998 Apr; 15(4):641-9. PubMed ID: 9587963
[TBL] [Abstract][Full Text] [Related]
13. [Antiviral properties of recombinant human lymphotoxin].
Denisov AA; Nikolaeva OG
Vopr Virusol; 1995; 40(6):277-9. PubMed ID: 8686267
[TBL] [Abstract][Full Text] [Related]
14. [Production of purified human recombinant alpha2b-interferon].
Mel'nik AI; Orlovskaia IV; Zholobak NM; Spivak NIa
Mikrobiol Z; 2012; 74(3):72-8. PubMed ID: 22830200
[TBL] [Abstract][Full Text] [Related]
15. The antiviral effect of human interferon alpha is dependent on phosphoinositide-derived messengers.
Cernescu C; Constantinescu SN; Baltă F; Popescu LM
Virologie; 1988; 39(1):3-6. PubMed ID: 2837002
[TBL] [Abstract][Full Text] [Related]
16. Variation in the binding of 125I-labeled interferon-beta ser to cellular receptors during growth of human renal and bladder carcinoma cells in vitro.
Ruzicka FJ; Schmid SM; Groveman DS; Cummings KB; Borden EC
Cancer Res; 1987 Sep; 47(17):4582-9. PubMed ID: 2957045
[TBL] [Abstract][Full Text] [Related]
17. [Methodological approaches to creating a liposomal form of human recombinant alpha 2-interferon].
Zolin VV; Luk'ianov AN; Nesterov AE; Kolokol'tsov AA; Torchilin VP; Popov VF; Vardanian NV; Antonov NA
Vestn Ross Akad Med Nauk; 1993; (2):29-31. PubMed ID: 7688615
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of relapsing-remitting multiple sclerosis with recombinant interferon-beta preparations].
Mäurer M; Gold R; Toyka KV; Rieckmann P
Nervenarzt; 2001 Feb; 72(2):108-16. PubMed ID: 11256144
[TBL] [Abstract][Full Text] [Related]
19. Production, purification and biological properties of an Escherichia coli-derived recombinant porcine alpha interferon.
Lefèvre F; L'Haridon R; Borras-Cuesta F; La Bonnardière C
J Gen Virol; 1990 May; 71 ( Pt 5)():1057-63. PubMed ID: 1693161
[TBL] [Abstract][Full Text] [Related]
20. Effects of interferon beta ser and transforming growth factor beta on prostatic cell lines.
Goldstein D; O'Leary M; Mitchen J; Borden EC; Wilding G
J Urol; 1991 Oct; 146(4):1173-7. PubMed ID: 1895445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
